R Is Acyclic Patents (Class 514/625)
-
Patent number: 8288442Abstract: A method for the treatment or prevention of pain and/or a headache disorder using a derivative of a valproic acid amide or a 2-valproenic acid amide, as well as pharmaceutical compositions comprising these derivatives or compounds.Type: GrantFiled: June 24, 2009Date of Patent: October 16, 2012Assignee: Yissum Research Development Company of The Hebrew University of JerusalemInventors: Mitchell Shirvan, Meir Bialer
-
Patent number: 8252520Abstract: The present invention provides methods and compounds for inhibiting HEC1 activity for the treatment of diseases involving cell hyperproliferation, e.g. cancer. The present invention also provides methods of identifying compounds for inhibiting HEC1 activity.Type: GrantFiled: October 14, 2003Date of Patent: August 28, 2012Assignee: Taivex Therapeutics CorporationInventors: Wen-Hwa Lee, Phang-Lang Chen, Yumay Chen
-
Publication number: 20120214858Abstract: Imidamide (amidine) analogs that can inhibit the activity of sphingosine kinase 1 and sphingosine kinase 2 (SphK1 & SphK2) are provided. The compounds can prevent angiogenesis in tumors.Type: ApplicationFiled: August 16, 2010Publication date: August 23, 2012Applicant: University of Virginia Patent FoundationInventors: Kevin R. Lynch, Timothy L. Macdonald, Thomas P. Mathews, Andrew Kennedy, Yugesh Kharel
-
Publication number: 20120214852Abstract: The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are alkoxyl derivative compounds and pharmaceutical compositions comprising these compounds. The subject compositions are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.Type: ApplicationFiled: November 8, 2011Publication date: August 23, 2012Applicant: Acucela Inc.Inventors: Ian L. Scott, Vladimir A. Kuksa, Mark W. Orme, Thomas Little, Anna Gall, Feng Hong
-
Publication number: 20120195861Abstract: Described herein are the use of peripheral blood derived germline stem cells and their progenitors, methods of isolation thereof, and methods of use thereof.Type: ApplicationFiled: January 14, 2011Publication date: August 2, 2012Applicant: The General Hospital CorporationInventors: Jonathan L. Tilly, Joshua Johnson
-
Publication number: 20120172326Abstract: The present invention refers to a moisturizing mixture for sensitive skins, atopic dermatitis and/or Ichthyosis vulgaris containing a synergistic combination among its constituents, and cosmetic and/ pharmaceutical compositions containing said moisturizing mixture. The invention also refers to a moisturizing mixture comprising a synergistic combination between at least one cutaneous-barrier repairing agent; NMF-precursor amino acids; and at least one filagrin-synthesis stimulating agent. Cosmetic and/or pharmaceutical compositions comprising said moisturizing mixture and a physiologically acceptable carrier are also described in the present invention.Type: ApplicationFiled: November 27, 2009Publication date: July 5, 2012Applicant: Natura Cosmeticos S.A.Inventors: Patricia Da Luz Moreira, Adriano Tadeu Siqueira Jorge, Juliana Palmeira Portugal Marques, Jean Luc Gesztesi, Philip Leite Ribeiro, Sara Rocha
-
Publication number: 20120165360Abstract: The invention provides amino- and amido-aminotetralin compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, and n are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.Type: ApplicationFiled: March 5, 2012Publication date: June 28, 2012Applicant: THERAVANCE, INC.Inventors: Sean G. Trapp, Michael R. Leadbetter, Daniel D. Long, Lan Jiang, Sabine Axt
-
Publication number: 20120149773Abstract: Disclosed is herein a composition comprising hexamidines, derivatives thereof, or pharmaceutically acceptable salts thereof; and retinoids, derivatives thereof, or pharmaceutically acceptable salts thereof, as an active ingredient. The composition of the present invention has effects for preventing, improving or treating acne; controlling sebum; pore-controlling; and preventing, improving or treating skin pigmentation. Also, the composition of the present invention could alleviate skin-irritations caused with retinoids by including ceramides.Type: ApplicationFiled: August 20, 2010Publication date: June 14, 2012Applicant: AMOREPACIFIC CORPORATIONInventors: Jong Hee Park, Shin Young Park, Hong-Ju Shin, Do-Hoon Kim, Chang-Geun Yi, Won Seok Park, Hyun Ju Koh, Jeong-Hwan Kim, Hyoung Jun Kim
-
Publication number: 20120141563Abstract: The present invention relates to a pharmaceutical composition to be parenterally administered, including submicronic ester particles of docosahexaenoic acid, dispersed in an aqueous phase using a mixture of at least two surfactants selected from among a) at least one polyoxyethylene fatty acid ester and b) at least one phospholipid derivative. The present invention also relates to the method for preparing said pharmaceutical composition.Type: ApplicationFiled: August 11, 2010Publication date: June 7, 2012Applicant: PIERRE FABRE MEDICAMENTInventors: Elie Leverd, Peter Van Hoogevest, Elsa Kung, Mathew Leigh
-
Patent number: 8188313Abstract: Compounds of formula wherein the variable are defined in the specification, are used in compositions which stimulate T cell responses.Type: GrantFiled: September 13, 2011Date of Patent: May 29, 2012Assignees: The University of Birmingham, Chancellor Masters and Scholars of the University of Oxford, Ludwig Institute for Cancer ResearchInventors: Vincenzo Cerundolo, Richard Schmidt, Gopal Reddy, Rengarajan Balamurugan, Gerd Ritter, Gurdyal Besra, Mariolina Salio, Jonathan Silk
-
Publication number: 20120129894Abstract: The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are alkoxyl derivative compounds and pharmaceutical compositions comprising these compounds. The subject compositions are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.Type: ApplicationFiled: May 19, 2011Publication date: May 24, 2012Applicant: Acucela Inc.Inventors: Ian L. Scott, Vladimir A. Kuksa, Mark W. Orme, Thomas Little, Anna Gall, Feng Hong
-
Publication number: 20120122938Abstract: The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are alkoxyl derivative compounds and pharmaceutical compositions comprising these compounds. The subject compositions are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.Type: ApplicationFiled: November 8, 2011Publication date: May 17, 2012Applicant: Acucela Inc.Inventors: Ian L. Scott, Vladimir A. Kuksa, Mark W. Orme, Thomas Little, Anna Gall, Feng Hong
-
Publication number: 20120115808Abstract: The present invention relates to topical preparations containing N-palmitoyl-vanillamide having hyperalgesic activity. In particular, the invention relates to N-palmitoyl-vanillamide for use in the treatment of pathologies selected from: post-herpetic neuralgia, neuralgia of trigeminus, occipital neuralgia, dental neuralgia, glottopharyngeal neuralgia, uremic neuralgia, diabetic neuralgia, headache of different origin, neuropathic itch, neurogenic itch, uremic itch, vulvodinia, vulvar vestibulitis, ano-rectal pain and itch, balano-preputial pain and itch, painful urogenital disorders of dogs and cats, psoriasis-associated pruritus and pain, itching skin diseases (e.g. atopic dermatitis) in the human and veterinary field, muscular pain, pain of the tendon, osteoarthritis associated pain in humans, dogs and cats; painful eye diseases in the human and veterinary field, inflammatory pathologies of the oral cavity in the human and veterinary field.Type: ApplicationFiled: November 8, 2011Publication date: May 10, 2012Inventors: Francesco DELLA VALLE, Luciano De Petrocellis, Sabatino Maione, Vincenzo Di Marzo, Maria Federica Della Valle
-
Publication number: 20120108667Abstract: Disclosed herein are compounds, compositions, methods of treatment and synthetic methods for making compounds related to Ceramides and the use of Ceramides.Type: ApplicationFiled: October 31, 2011Publication date: May 3, 2012Inventors: Zdzislaw M. Szulc, Alicja Bielawska, Yusuf A. Hannun
-
Publication number: 20120108661Abstract: The emulsion composition of the present invention contains (A) 0.001 to 10 wt. % of an organic compound having two or more hydroxyl groups, an inorganic value of 220 to 450, and an organic value of 300 to 1,000; (B) 0.001 to 10 wt. % of an organic compound having one hydroxyl group, an inorganic value of 100 to 200, and an organic value of 280 to 700; (C) 0.001 to 10 wt. % of a compound represented by formula (2): wherein R1 is a C4 to C30 hydrocarbon group; Z is a methylene group, a methine group, or an oxygen atom; X1, X2, X3 is a hydrogen atom, a hydroxyl group, or an acetoxy group; X4 is a hydrogen atom, an acetyl group, or a glyceryl group; each of R2 and R3 a hydrogen atom, a hydroxyl group, a hydroxymethyl group, or an acetoxymethyl group; R4 is a C5 to C60 hydrocarbon group; and R5 is a hydrogen atom or a hydrocarbon group containing 1 to 30 carbon atoms in total; (D) 0.00012 to 10 wt.Type: ApplicationFiled: July 6, 2010Publication date: May 3, 2012Applicant: KAO CORPORATIONInventors: Masanori Orita, Tomokazu Yoshida, Chihiro Ueyama
-
Publication number: 20120100229Abstract: The present invention includes a method of treating or preventing a CNS white matter injury in a patient in need thereof. The invention also includes a method of stimulating proliferation of a CNS cell in a patient in need thereof.Type: ApplicationFiled: March 25, 2010Publication date: April 26, 2012Inventor: Scott Rivkees
-
Patent number: 8163956Abstract: A compound of the formula (I): wherein R1, R2, R3, R4, Ar, A, n and m are defined herein, is disclosed as a GlyT1 inhibitor; pharmaceutical compositions containing the compound of the formula (I) are also disclosed as are their use in medicine, for example in the treatment of schizophrenia.Type: GrantFiled: June 13, 2006Date of Patent: April 24, 2012Assignee: Merck Sharp & Dohme Corp.Inventors: Wesley Peter Blackaby, Ian Thomas Huscroft, Linda Elizabeth Keown, Richard Thomas Lewis, Piotr Antoni Raubo, Leslie Joseph Street, Christopher George Thomson, Joanne Thomson
-
Publication number: 20120093742Abstract: A method of modulating the flavour of an orally-receivable product, such as a foodstuff, beverage, dentifrice or medicine, comprising the addition thereto of a flavour-modulating proportion of at least one compound of the formula I in which X is selected from CHOH, C?O, CH2—CO and CH?C(OH), Y is selected from C1-C7 linear and branched alkyl and CH2CH2OH, Z is selected from CH3 and a moiety of the formula II in which the wavy bond represents bond linking Z to X and R1 and R2 are selected from the possibilities (i) both hydrogen; (ii) independently OH and OCH3; and (iii) R1 and R2 together with their bonds to the phenyl ring form a ring of the formula —O—CH2—O—; such that, when Z is CH3, X is C?O and Y is CH2CH2OH.Type: ApplicationFiled: June 24, 2010Publication date: April 19, 2012Applicant: Givaudan S.A.Inventors: Abdelmajid Kaouas, Harry Renes, Alexander P. Tondeur, Cornelis Winkel
-
Publication number: 20120083532Abstract: The present invention relates to the use of a compound represented by the general formula (I), and pharmaceutically acceptable salts thereof, wherein: n is an integer from 2 to 5; p is an integer from 0 to 4; R1 is selected from the group consisting of a hydroxyl group, an alkoxy group, a thiol group, a thioether group, and an amino group, wherein at least two of R1 is a hydroxyl group, a thiol group or an amino group, with the proviso that wherein n is 2, R1 is not on the carbon-2 position and the carbon-5 position of the phenyl group; R2 and R3 are independently a methylene group or a nucleophile, with the proviso that at least one of R2 and R3 is a nucleophile group; Z is an oxygen (O) atom or sulfur (S) atom; T is hydrogen or an optionally substituted aliphatic group; in the manufacture of a medicament for treating a patient in need of cell therapy.Type: ApplicationFiled: June 11, 2010Publication date: April 5, 2012Inventors: Mark Richards, Chee Wee Phoon, Mun Kin Lee
-
Publication number: 20120083533Abstract: A therapy for renal diseases, in particular renal diseases which develop in diabetic patients or patients who have been subjected to a treatment with an antitumor chemotherapy such as a platinum derivative and more generally cytotoxic drugs at renal level for treating of neoplastic diseases. More particularly, the present invention relates to palmitoylethanolamide and diethanolamide of fumaric acid for use in the treatment of renal diseases, in particular those caused by dysmetabolic diseases or by toxic or chemotherapy agents, such as platinum derivatives. Palmitoylethanolamide is used preferably in micronized or ultra-micronized form. Diethanolamide of fumaric acid is used preferably in aqueous solution.Type: ApplicationFiled: October 3, 2011Publication date: April 5, 2012Inventors: Francesco Della Valle, Raffacle Migliaccio, Maria Federica Della Valle
-
Publication number: 20120070473Abstract: A method for inhibiting formation of adhesions following abdominal surgery which involves application of an anti-static fatty acid ethoxylated amide (Cocamide DEA) in a matrix that is placed in the peritoneal cavity at the conclusion of an abdominal surgery and which releases this anti-adhesive chemical over a predetermined time in a range up to seven days. Tests conducted on laboratory rats established that the method reduced the incidence of adhesions from 100 percent (100%) in a test model to near zero in the majority of treated animals. In an alternative embodiment, andrographalide was delivered via a pump with similar results. In still another embodiment, an effective amount of 50% phosphatidylchorene and propylene glycol was delivered, via a pump, into the abdominal cavity, again with similar results.Type: ApplicationFiled: November 22, 2011Publication date: March 22, 2012Applicant: ANHESE LLCInventor: John P. Delaney
-
Patent number: 8124637Abstract: A series of novel anthra[1,2-d]imidazole-6,11-dione derivatives, and the preparation method and application of said derivatives, wherein said application includes a pharmaceutical composition containing said derivatives for treating cancer, and said application involves effects of said derivatives for inhibiting telomerase activity, inhibiting the growth of cancer cell, treating cancer and the like.Type: GrantFiled: February 25, 2010Date of Patent: February 28, 2012Assignee: National Defense Medical CenterInventor: Hsu-Shan Huang
-
Publication number: 20120022165Abstract: The present invention is directed to transdermal compositions and the uses thereof. These compositions include at least one of the following components: a C1-C6 dialkyl, C12-C30 dialkyl quaternary ammonium salt, a C12-C30 fatty acid, a nitrogenous organic base, C12-30 fatty alcohol, monoglyceride or the reaction products thereof.Type: ApplicationFiled: September 30, 2011Publication date: January 26, 2012Applicant: MICRODERMIS CORPORATIONInventors: Griscom Bettle, III, William S. Coury
-
Publication number: 20120016032Abstract: Cosmetic compositions comprising calcium citrate and at least one N-acylated aminoalcohol according to formula (I). Provided is a method of treating aged skin, comprising topically applying to the aged skin a composition comprising a compound of Formula (I) in an amount effective to provide an anti-ageing effect. The compound of Formula (I) is used to prevent skin and/or to help to maintain or improve moisture retention and/or to fight against the signs of skin ageing. The N-acylated aminoalcohol of formula (I) acts as a ceramidase inhibitor. The combination of at least one compound of formula (I) and calcium citrate stimulates keratinocyte differentiation.Type: ApplicationFiled: March 16, 2010Publication date: January 19, 2012Applicant: Cognis IP Management GmbHInventors: Philippe Moussou, Olga Freis, Louis Danoux, Philippe Grisoni, Laurent Bailly
-
Publication number: 20120009253Abstract: Use of an anti-inflammatory agent such as povidone iodine for the preparation of a pharmaceutical composition for the treatment of diseases of the lower respiratory tract which are susceptible to the administration of such agents.Type: ApplicationFiled: September 22, 2011Publication date: January 12, 2012Inventors: Wolfgang Fleischer, Karen Reimer
-
Publication number: 20110306672Abstract: This invention relates to certain ceramide-analogues of FTY720 (2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol; fingolimod). In particular, the present invention relates to pharmaceutical compositions comprising these compounds, as well as processes for their preparation and their use in the treatment of autoimmune conditions, such as multiple sclerosis.Type: ApplicationFiled: February 23, 2010Publication date: December 15, 2011Applicant: NOVARTIS AGInventors: Volker Brinkmann, Guido Jordine, Markus Zollinger, Claudia Sayer
-
Publication number: 20110288037Abstract: The present invention relates to a pharmaceutical composition consisting of amides of mono- and di-carboxylic acids and hydroxystilbenes, and may be used for the treatment of pathologies caused, sustained and/or characterised by an abnormal general response of the immune system, in both humans and animals.Type: ApplicationFiled: August 3, 2011Publication date: November 24, 2011Inventors: Francesco Della Valle, Maria Federica Della Valle, Gabriele Marcolongo, Gianpiero Ravagnan, Vincenzo Di Marzo
-
Publication number: 20110263714Abstract: The reverse vesicle composition of the present invention includes (A) a sphingosine represented by formula (1) (wherein R1 represents a C4 to C30 linear alkyl group which may be substituted by a hydroxyl group, a carbonyl group, or an amino group; Y represents a methylene group, a methine group, or an oxygen atom; each of X1, X2, and X3 represents a hydrogen atom, a hydroxyl group, or an acetoxy group; X4 represents a hydrogen atom, an acetyl group, or a glyceryl group, or forms an oxo group together with the adjacent oxygen atom (wherein when Y is a methine group, one of X1 and X2 is a hydrogen atom, and the other is absent, and when X4 forms an oxo group, X3 is absent); each of R2 and R3 represents a hydrogen atom, a hydroxyl group, a hydroxymethyl group, or an acetoxymethyl group; a is a number of 2 or 3; each of (R)a represents a hydrogen atom, an amidino group, or a linear-chain alkyl group optionally having a substituent selected from among a hydroxyl group, a hydroxyalkoxy group, an alkoxy group, and aType: ApplicationFiled: August 8, 2008Publication date: October 27, 2011Applicant: Kao CorporationInventor: Koji Okubo
-
Patent number: 8039670Abstract: There are disclosed compound of formula I, in which R1 represents a hydrophobic moiety adapted to occupy the C? channel of human CDId, R2 represents a hydrophobic moiety adapted to occupy the A? channel of human CDId, such that R1 fills at least at least 30% of the occupied volume of the C? channel compared to the volume occupied by the terminal nC14H29 of the sphingosine chain of ?-galactosylceramide when bound to human CDId and R2 fills at least 30% of the occupied volume of the A? channel compared to the volume occupied by the terminal nC25H51 of the acyl chain of ?-galactosylceramide when bound to human CDId R3 represents hydrogen or OH, Ra and Rb each represent hydrogen and in addition, when R3 represents hydrogen, Ra and Rb together may form a single bond, X represents or —CHA(CHOH)nY or —P(=0)(0?)0CH2(CH0H)mY, in which Y represents CHB1B2, n represents an integer from 1 to 4, m represents 0 or 1, A årepresents hydrogen, one of B1 and B2 represents H, OH or phenyl, and the other represents hydrogen or oType: GrantFiled: October 25, 2006Date of Patent: October 18, 2011Assignees: Ludwig Institute for Cancer Research, Chancellor Master and Scholars of the University of Oxford, The University of BirminghamInventors: Vincenzo Cerundolo, Richard Schmidt, Gopal Reddy, Rengarajan Balamurugan, Gerd Ritter, Gurdyal Besra, Mariolina Salio, Jonathan Silk
-
Publication number: 20110229540Abstract: A cosmetic formulation comprising porous silicon is described.Type: ApplicationFiled: September 30, 2009Publication date: September 22, 2011Inventors: Leigh Canham, Tanya Monga
-
Patent number: 8017651Abstract: Compositions for treating or preventing fat maldistribution or hyperlipidemia resulting from anti-retroviral treatment of HIV-1 infection are disclosed. The compositions contain a conjugated fatty acid or alcohol and at least one member selected from the group consisting of a thiol-containing compound and a bioavailable form of trivalent chromium. Methods of treating a subject suffering from HIV-associated fat maldistribution or hyperlipidemia by administering a composition that includes a conjugated fatty acid or conjugated fatty alcohol and at least one member selected from the group consisting of a thiol-containing compound and a bioavailable form of trivalent chromium are similarly provided.Type: GrantFiled: October 31, 2003Date of Patent: September 13, 2011Assignee: Bionexus, Ltd.Inventors: Linda M. Pacioretty, John G. Babish
-
Publication number: 20110212173Abstract: There is described a pharmaceutical composition for controlled release of an active compound wherein the active compound is selected from the group comprising tramadol, resveratrol, acetaminophen, xorphanol, cinfenoac, furcloprofen, bismuth subsalicylate, enofelast, triflusal, ketorfanol, indriline, furofenac, cizolirtine, dacemazine, demelverine, and fenethazine, and derivatives and/or combinations thereof for the treatment or alleviation of depression. More particularly, there is described an abuse resistant pharmaceutical composition for the treatment of inter alia, depression and controlled release pharmaceutical compositions of related thereto.Type: ApplicationFiled: June 17, 2009Publication date: September 1, 2011Applicant: e-Therapeutics PleInventors: Malcolm Philip Young, Olusola Clement Idowu, Philip McKeown
-
Patent number: 8003617Abstract: The invention provides methods of treating a diabetic subject comprising administering a glucosylceramide synthase inhibitor to the subject.Type: GrantFiled: November 9, 2005Date of Patent: August 23, 2011Assignee: Genzyme CorporationInventors: Seng H. Cheng, Nelson S. Yew, Ronald K. Scheule, Hongmei Zhao
-
Publication number: 20110200669Abstract: Compositions and a methods are described for treating disorders of the small and large bowel, such as Crohn's disease, ulcerative colitis and irritable bowel syndrome, without producing any treatment-related systemic side effects and with minimal or no abdominal discomfort. A method of administration of civamide that is incorporated into soft gelatin capsules and administered with meals is described. Surprisingly, the method provides for diminishment of pain and inflammation of the small and large bowel without producing any systemic side effects or significant abdominal discomfort.Type: ApplicationFiled: February 15, 2010Publication date: August 18, 2011Applicant: WINSTON LABORATORIES, INC.Inventor: Joel E. Bernstein
-
Publication number: 20110195018Abstract: Disclosed are oxo-hydroquinazolines that are useful as selective TSHR agonists. The compounds may be used for detecting or treating thyroid cancer, or treating a bone degenerative disorder.Type: ApplicationFiled: October 20, 2008Publication date: August 11, 2011Inventors: Marvin C. Gershengorn, Susanne Neumann, Bruce M. Raaka, Craig J. Thomas, James Inglese, Noel T. Southall, Steven Titus, Wei Zheng, Wenwei Huang, Gerd Krause, Gunnar Kleinau
-
Publication number: 20110190285Abstract: The present invention provides methods of treating a botulinum toxin related condition in a subject. In certain embodiments, the methods involve administering a compound of the following formulas: (I), (II), (III), (IV), (V).Type: ApplicationFiled: August 26, 2009Publication date: August 4, 2011Applicant: ABSOLUTE SCIENCE, INC.Inventors: Alan Jacobson, Scott Moe
-
Publication number: 20110182833Abstract: Compounds of formula (I) wherein R1-R5, n and m have the same meaning as given in the description, having cooling properties are disclosed. Furthermore a process of their production and consumer products comprising them are disclosed.Type: ApplicationFiled: December 4, 2008Publication date: July 28, 2011Inventors: Stefan Michael Furrer, Thomas Scott McCluskey
-
Patent number: 7981923Abstract: Compounds of the formula I, II or III: or pharmaceutically acceptable salts thereof, wherein m, n, q, Ar, R1, R2, R3, R4 and R5 are as defined herein. Also provided are methods for preparing, compositions comprising, and methods for using compounds of formulas I-III.Type: GrantFiled: January 26, 2010Date of Patent: July 19, 2011Assignee: Roche Palo Alto LLCInventors: Ralph New Harris, III, James M. Kress, David Bruce Repke, Russell Stephen Stabler
-
Publication number: 20110171313Abstract: The present invention relates to a composition for pharmaceutical or veterinary use, comprising palmitoylethanolamide. In particular, the present invention relates to a pharmaceutical composition for human or veterinary use, containing a therapeutically efficient amount of palmitoylethanolamide in the ultra-micronized form, wherein more than 90% by weight of palmitoylethanolamide has particle sizes lower than 6 microns, together with pharmaceutically acceptable excipients.Type: ApplicationFiled: September 7, 2009Publication date: July 14, 2011Inventors: Francesco Della Valle, Gabriele Marcolongo, Maria Federica Della Valle
-
Publication number: 20110136668Abstract: System, including methods compositions, and kits, for controlling the growth of fungi and other pathogens in plants using at least one alkamide, which may function by increasing or eliciting natural defense mechanisms of the plants against such pathogens.Type: ApplicationFiled: August 5, 2009Publication date: June 9, 2011Inventors: José López-Bucio, Jorge Molina-Torres, Luis Rafael Herrera-Estrella
-
Patent number: 7955607Abstract: Provided are a method for evaluating evenness of suplatast tosilate crystals; stable suplatast tosilate crystals exhibiting evenness in optical purity; and a method for producing the suplatast tosilate crystals. The method for evaluating evenness of suplatast tosilate crystals includes: (a) a step of adding a solvent to suplatast tosilate crystals to thereby dissolve 3% or less of the crystals in the solvent, and subjecting a portion of the supernatant of the resultant suspension to optical purity measurement, and (b) a step of adding a solvent to the remaining suspension to thereby dissolve the entirety of the suspension in the solvent, and subjecting a portion of the resultant solution to optical purity measurement, wherein the optical purity as measured in the step (a) is compared with the optical purity as measured in the step (b). The suplatast tosilate crystals exhibits excellent evenness and thermal stability. The method for producing the suplatast tosilate crystals is also provided.Type: GrantFiled: July 13, 2005Date of Patent: June 7, 2011Assignee: Taiho Pharmaceutical Co., Ltd.Inventors: Takanori Ushio, Keiko Nagai
-
Publication number: 20110130448Abstract: The present invention relates to a compound of the formula: R-AR—O—Y—R? Wherein R represents one or more members selected from H, alkoxy, benzyloxy, aldehyde, halogen, carboxylic acid, —NO2, —NH2, —NHCOCH3, and —NH—Y—R?, which is attached directly to AR or attached through an aliphatic chain. The carboxylic acid moiety in R includes but is not limited to the following carboxylic acids: benzoic acids, cinnamic acids, ferulic acid, caffeic acid, syringic acid, salicyclic acid, vanillic acid, phenylacetic acids, phenylpropionic acids, and sinapinic acid. -AR—O— is a biologically active phenolic moiety comprising 1 to 6 substituted or unsubstituted aryl rings that are directly bonded to each other, fused together, or joined through a linking group.Type: ApplicationFiled: December 7, 2010Publication date: June 2, 2011Applicant: Bezwada Biomedical LLCInventor: Rao S. Bezwada
-
Publication number: 20110130456Abstract: A hair growth regulating agent containing, as an active ingredient, a compound represented by the following formula (I): [wherein R1 represents a substituted or unsubstituted, linear or branched C2 to C25 alkyl group; a group represented by the following formula (II): (wherein R1? represents a substituted or unsubstituted, linear or branched C2 to C20 alkylene group, or —(CH2)n-{O—(CH2)m}o-O—(CH2)p- in which each of n, m, o, and p is an integer from 1 to 6; X? represents —CO—NH—, —O—CO—O—, —NH—CO—, —CO—O—, —O—CO—, or —O—; Y? represents a substituted or unsubstituted C1 to C4 alkylene group; R2? represents a hydrogen atom or a C1 to C4 alkyl group; R3? represents a C1 to C4 alkyl group; and when R2? and R3? each represent a C1 to C4 alkyl group, the two alkyl groups may be identical to or different from each other); or a group represented by the following formula (III): (wherein R1?, X?, and Y? have the same meanings as defined above; R4?, R5?, and R6?, which may be identical to or different from one another,Type: ApplicationFiled: August 4, 2009Publication date: June 2, 2011Applicant: Kao CorporationInventors: Yasuto Suzuki, Naoko Morisaki, Michiyo Sasajima
-
Publication number: 20110118347Abstract: A compound of the formula CH3(CH2)n—RA—(CH2)m-(CH?CH)q—(CH2)p—X wherein RA=(a); q=0 or 1; m and p are independently selected integers of at least 1; n=0 or an integer of at least 1; X is a polar group selected from —CO2RS, where Rs?H, Na, K, —NHRI, —NRIRII or RIII; —CH3OH; —CH3NH2; —CH3NHRI; or —CH3NRIRII; wherein RI, RII and RIII are independently selected from C1-C6 alkyl or an aryl group, preferably a hydrophilically substituted C1-C6 alkyl or aryl group, or RIII is an esterified glycol; and wherein 20>m+n+p+2q?2; is useful for the treatment of ringworm infection caused by Trichophyton tonsurans.Type: ApplicationFiled: May 29, 2009Publication date: May 19, 2011Applicant: Vernolix LimitedInventor: Michael William Fowler
-
Publication number: 20110086761Abstract: The present invention relates to fungicidal compositions and their use for controlling oomycete pathogen induced disease or diseases in one or more plants.Type: ApplicationFiled: October 13, 2010Publication date: April 14, 2011Applicant: DOW AGROSCIENCES LLCInventors: Norman R. Pearson, Lei Liu, Robert J. Ehr, John M. Atkinson
-
Publication number: 20110076321Abstract: A self-adhesive polymer matrix which comprises a polymer that forms a gel in water, water, a sea algae extract, and a monohydric or polyhydric alcohol.Type: ApplicationFiled: September 22, 2010Publication date: March 31, 2011Applicant: BEIERSDORF AGInventors: Karl-Heinz WOELLER, Thorsten BERG, Inge KRUSE, Rainer WOLBER
-
Publication number: 20110071118Abstract: A novel pharmaceutical composition is provided by which nonsteroidal anti-inflammatory drugs (NSAIDs) are added directly to phospholipid-containing oil such as lecithin oils or to a bio-compatible oil to which an phospholipid has been added to make a NSAID-containing formulation that possess low gastrointestinal (GI) toxicity and enhanced therapeutic activity to treat or prevent inflammation, pain, fever, platelet aggregation, tissue ulcerations and/or other tissue disorders. The composition of the invention are in the form of a non-aqueous solution, paste, suspension, dispersion, colloidal suspension or in the form of an aqueous emulsion or microemulstion for internal, oral, direct or topical administration.Type: ApplicationFiled: September 16, 2010Publication date: March 24, 2011Applicant: The Board of Regents of the University of Texas SystemInventor: Lenard M. Lichtenberger
-
Publication number: 20110071100Abstract: The subject of the invention provides a pharmaceutical composition comprising a sulfobetaine, a sulfobetaine for therapy, uses thereof and methods of treating cancer obesity, age related macular degeneration or neurodegenerative diseases comprising administering a composition comprising a sulfobetaine.Type: ApplicationFiled: May 5, 2009Publication date: March 24, 2011Applicant: TILTAN PHARMA LTD.Inventors: Shmuel A. Ben-Sasson, Arie Dagan
-
Publication number: 20110065801Abstract: The invention relates to the enzymatic synthesis of sphingolipids and compositions comprising sphingolipids from lysosphingolipids and carboxylic esters, and to cosmetic, dermatological or pharmaceutical formulations which comprise these sphingolipids or compositions.Type: ApplicationFiled: May 22, 2009Publication date: March 17, 2011Applicant: EVONIK GOLDSCHMIDT GMBHInventors: Frank Hollmann, Oliver Thum, Pawel Grzebyk, Christoph Toelle
-
Publication number: 20110064681Abstract: The present invention relates to cosmetic preparations comprising novel polyurethanes or mixtures thereof as means for modifying rheological properties.Type: ApplicationFiled: May 6, 2009Publication date: March 17, 2011Applicant: BASF SEInventors: Volker Wendel, Helmuth Völlmar, Holger Türk, Markus Buchmann, Valerie Andre, Matthias Laubender, Claudia Wood, Andree Dragon